Testing effectiveness (Phase 2)Ended earlyNCT02368691
What this trial is testing
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Who this might be right for
Triple Negative Breast Cancer
GTx 32